PDB154 Cost Implications Of Early Discontinuation And Restart Of Insulin In The Treatment Of Type 2 Diabetes Mellitus  by Ascher-Svanum, H. et al.
A264  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  
regulatory reviews faster than the EMA while beginning regulatory review first in 
each case. Three of the four regulatory decisions in which the FDA was slower were 
outliers in terms of approval time. Additionally, when looking at the median, the 
FDA approved these moieties 77 days faster than the EMA while Downing’s findings 
only showed a 44-day differential. This was expected because the analysis included 
the EC decision takes about 2 months on average. ConClusions: After updating 
the data, restricting it to a particular subset of diabetes treatments, and altering 
the EMA regulatory endpoint, Downing et al’s findings not only still hold true, but 
become even more pronounced.
PDB153
DelayeD TreaTmenT moDificaTions for PaTienTs WiTh TyPe 2 DiaBeTes 
melliTus (T2Dm) WiTh Very Poor Glycemic conTrol
Schwab P.1, Saundankar V.1, Bouchard J.R.2, Moretz C.1, Baltz J.3
1Comprehensive Health Insights, Louisville, KY, USA, 2Novo Nordisk, Inc., Princeton, NJ, USA, 
3Humana Inc., Louisville, KY, USA
objeCtives: Risk of cardiovascular disease, retinopathy, nephropathy, and neu-
ropathy increases substantially when HbA1c> 7% (suboptimal glycemic control), but 
timely therapy intensification may reduce risk. When HbA1c> 9% (very poor control) 
AACE recommends that triple therapy (asymptomatic patients) or insulin (sympto-
matic patients) be initiated to reach HbA1c≤ 6.5% for patients without concurrent 
illness and at low hypoglycemic risk. Clinical inertia (failure to intensify therapy in 
a timely manner) leads to poor glycemic control. The objective of this study was to 
examine time to treatment modifications in patients with HbA1c≥ 9%. Methods: 
Medical, laboratory, and pharmacy claims data for Humana’s fully insured commer-
cial and Medicare membership were used for this study. Patients with T2DM with 
first HbA1c≥ 9% date (index-date) between Jan 1, 2008–Dec. 31, 2009 were identified. 
Baseline characteristics were obtained within 12 months preceding the index-date. 
Treatment modification was defined as addition or switch of an antidiabetic drug 
class. Study outcome (delay in treatment modification) was assessed as the days 
until modification within the 36-months post-index period. Results: There were 
8,464 patients identified (mean age 66 years, 48% male, 82% from the southern US, 
mean Deyo-Charlson Comorbidity Index 2.54, mean Diabetes Complications Severity 
Index 2.17). Approximately 83% of patients experienced modification within 36 
months; 47% within 90 days of HbA1c≥ 9% index date, 7% between 91-180 days, 5% 
between 181-365 days, while 24% were > 365 days. Around 20% of patients received 
insulin as a modification. Although the proportion of patients receiving triple 
therapy (≥ 3 classes) was still low (23%) at 12 months post-index, it increased from 
10% at baseline. ConClusions: Many patients in poor control receive insufficient 
therapy as recommended by treatment guidelines. Even though additional agents 
were added for some patients, those receiving insulin or triple therapy were low. For 
patients with HbA1c≥ 9%, prompt treatment intensification is needed to improve 
glycemic control and limit complications.
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objeCtives: This study examined different types of medical costs associated with 
early discontinuation (ED) of insulin therapy and with restarting of insulin among 
ED patients in the treatment of type 2 diabetes mellitus (T2DM). Methods: Truven’s 
Health Analytics Commercial Claims and Encounters database from 1/1/08 through 
12/31/11 were utilized. ED was defined as discontinuation of insulin therapy for at 
least 30 days in the first 90 days post initiation. Generalized linear models with log-
link were used to examine the association between ED and total medical costs, acute 
care (hospitalization and emergency room) costs, outpatient costs, diabetes-related 
drug costs and all-cause drug costs. Among ED patients, the association between 
restarting insulin therapy and costs were also examined. Analyses controlled for 
patient characteristics, index medication prescribed, patient general health, comor-
bidities, prior resource utilization, and prior medication utilization. Results: Most 
(82% of 74,399) individuals discontinued insulin therapy in the first year post initia-
tion and 75% of these patients were ED. Compared to non-ED, ED was associated 
with 9.6% higher acute care costs (P= 0.0003), while outpatient costs, diabetes-related 
drug costs, all-cause drug costs and total medical costs were all significantly lower 
among ED patients. Among the ED cohort, 90% restarted therapy over the post-
period, with 53% restarting within 4 months. Compared to non-restart, the restart of 
insulin therapy after ED was associated with 11.3% higher acute care costs (P= 0.033), 
24.0% higher outpatient costs (P< 0.001), 80.2% higher all-cause drug costs (P< 0.001, 
and 30.3% higher total medical costs (P< 0.001). ConClusions: Current findings 
suggest that during the first three months following initiation of insulin therapy 
for T2DM, the ED of insulin therapy and its restart are associated with higher acute 
care costs. Such costs are often considered avoidable or modifiable costs and tend 
to signal poorer long-term treatment outcomes.
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objeCtives: To compare recent trends in treatment pattern for diabetes between 
2002 and 2010. Methods: A cross-sectional study of expenditures was carried 
for representative sample of civilian, noninstitutionalized U.S individuals with 
diabetes from the Medical Expenditure (MEPS) 2002-2010. Expenditures include 
all sources of payment for oral anti-diabetic medications, insulin, and non-insulin 
injectables. We inflated 2002 dollar values to 2010 values using the consumer price 
index. Results: From 2002 to 2010, the estimated number of persons reporting 
as pellets was higher than those with other formulations. Patients starting with a 
patch demonstrated the highest switching rate compared to other formulations.
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objeCtives: DPP-4 inhibitors produce a modest improvement in HgbA1C with 
relatively few adverse effects. Little is known about the characteristics and treat-
ment patterns of patients receiving DPP-4 inhibitors in the US. The objectives of 
the current study were to characterize patients prescribed DPP-4 inhibitors and 
examine patterns of anti-diabetic medication use in the one year following their 
initiation. Methods: Data were obtained from Humedica’s National Electronic 
Health Record-Derived Longitudinal Patient-Level Database (2007–2011). The study 
cohort included all adult patients with T2DM who received a first prescription for a 
DPP-4 inhibitor during the study period and who had at least one HgbA1C value at 
baseline. Baseline patient demographics, clinical characteristics and anti-diabetic 
medication use in the one-year follow-up period were assessed. Cox proportional 
hazard models were used to assess independent predictors of the aggregate out-
come of switching or augmentation. Results: Of the 8700 patients in the study 
cohort, 84% were older than 50, and 52% were female; the mean BMI was 34.4 and 
mean HgbA1c at baseline was 7.81%. Overall, 2226 (25.6%) patients switched or 
augmented therapy within the first year following DPP-4 inhibitor initiation after 
a mean of 6.1 months; the most frequently observed patterns included a switch 
to another oral agent (n= 1791, 20.6%) or to insulin (n= 306, 3.5%). Higher baseline 
HgbA1C (HR 1.20 [95% CI 1.14-1.26] for HgbA1C > 9% vs. < 7%) and higher BMI (HR 
1.11 [95% CI 1.06-1.16] for BMI ≥ 30 vs. 25-29) predicted higher rates of switching/
augmentation, while female gender (HR 0.92 [95% CI 0.89-0.95]) and younger age 0.42 
[95% CI 0.22-0.81]) predicted lower rates. ConClusions: In this US cohort, change 
in anti-diabetic treatment was relatively uncommon in the one year following ini-
tiation of a DPP-4 inhibitor. Baseline characteristics including HgbA1C, BMI and 
demographics can be used to inform the likelihood of switching or augmentation.
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objeCtives: Centers for Medicare and Medicaid Services (CMS) assess the per-
formance of health insurance plans using quality of care measures. This study 
assessed achievement of 8 diabetes-related quality measures at the patient 
level and examined whether achievement was associated with fewer complica-
tions. Methods: Claims and member-level quality data between January 2010 
and December 2011 were obtained from a Medicare Advantage Prescription Drug 
Insurance provider. Patients with type 1 or type 2 diabetes on the index date 
(January 1, 2011) and with 12 months of pre- and post-index continuous enroll-
ment were included. Quality of care and diabetes complications were assessed 
during the post-index year. The impact of quality metric achievement on new or 
worsening diabetes complications was assessed with a logistic regression model, 
which adjusted for baseline characteristics. Results: Cohort size ranged from 
159,454 to 4,464, depending on the quality measure and patient-level data avail-
ability. Most patients (> 80%) achieved LDL-C screening, nephropathy assessment, 
and medication adherence standards. Over 99% of patients met dosing standards 
for biguanides, sulfonylureas, and thiazolidinediones. Eye screening and use of 
appropriate anti-hypertensive treatments had lower achievement levels (50.3% 
and 54.2%, respectively). A majority (61%) of patients achieved HbA1c< 9%; 29% of 
patients achieved LDL-C control < 100mg/dl. Logistic regression estimates showed 
that failure to reduce HbA1c below 9% statistically significantly increased the 
risk of new or worsening diabetes complications [(OR, 1.12 (95% CI, 1.10-1.15); 
p< 0.0001)] as did failure to use anti-hypertensive treatment [(OR, 1.40, (95% CI, 
1.24-1.59); p< 0.0001]. ConClusions: Data from a 1-year observation period sug-
gests that attainment of CMS diabetes quality metrics was associated with lower 
new or worsening complication risk. Since the full impact of improved care may 
not be properly assessed within such a short time, follow-up longitudinal studies 
would shed light on the long-term impact of achieving quality measures.
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objeCtives: In 2012, Downing et al published a novel study in the NEJM that com-
pared the speed of regulatory agencies between 2001-2010, which demonstrated the 
FDA’s relative quickness. This paper narrows the scope to new non-insulin depend-
ent type II diabetes drugs approved by the EMA and FDA (using their respective 
websites) during 2005-2013, accounting for new drug approvals and legal updates 
to regulatory systems in a disease condition that has faced a plethora of regu-
latory challenges. Methods: Unlike Downing, this study looks at the European 
Commission’s (EC) decision, instead of the Committee for Medical Products for 
Human Use’s (CHMP) recommendation. A Marketing Authorization is issued upon 
EC decision, making it analogous with the data captured surrounding the FDA’s 
approval process. Additionally this analysis looks at the date submitted to the FDA 
and EMA as well as the approval date. The data consists of 12 non-insulin dependent 
moieties approved between 2005 and 2013. Results: Out of the 12 new treatments, 
10 were approved first by the FDA (83%). Additionally, the FDA began reviews before 
the EMA with a median time of 126.5 days. The FDA also completed 8 of the 12 
